Ampio Pharmaceuticals Inc (AMPE) Sees Large Increase in Short Interest

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the target of a large increase in short interest during the month of January. As of January 12th, there was short interest totalling 10,984,671 shares, an increase of 12.7% from the December 29th total of 9,749,519 shares. Based on an average daily trading volume, of 2,484,433 shares, the days-to-cover ratio is currently 4.4 days. Currently, 16.2% of the company’s stock are sold short.

A hedge fund recently bought a new stake in Ampio Pharmaceuticals stock. Creative Planning acquired a new stake in shares of Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 28,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $116,000.

Ampio Pharmaceuticals (NYSEAMERICAN AMPE) opened at $2.72 on Monday. The company has a market capitalization of $186.48, a P/E ratio of -13.60 and a beta of 0.51. Ampio Pharmaceuticals has a 1 year low of $0.38 and a 1 year high of $4.95.

Separately, ValuEngine upgraded Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 11th.

COPYRIGHT VIOLATION WARNING: “Ampio Pharmaceuticals Inc (AMPE) Sees Large Increase in Short Interest” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/29/ampio-pharmaceuticals-inc-ampe-sees-large-increase-in-short-interest.html.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply